Published in Am J Physiol Lung Cell Mol Physiol on October 01, 2000
Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med (2008) 2.35
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol (2009) 1.88
Divergent roles of glycolysis and the mitochondrial electron transport chain in hypoxic pulmonary vasoconstriction of the rat: identity of the hypoxic sensor. J Physiol (2001) 1.64
Mitochondrial reactive oxygen species regulate hypoxic signaling. Curr Opin Cell Biol (2009) 1.58
The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol (2008) 1.49
Oxidant and redox signaling in vascular oxygen sensing: implications for systemic and pulmonary hypertension. Antioxid Redox Signal (2008) 1.18
Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin Invest (2002) 1.04
ROS-dependent signaling mechanisms for hypoxic Ca(2+) responses in pulmonary artery myocytes. Antioxid Redox Signal (2010) 1.04
NADPH oxidase-derived ROS and the regulation of pulmonary vessel tone. Am J Physiol Heart Circ Physiol (2012) 0.99
Hypoxia-induced changes in pulmonary and systemic vascular resistance: where is the O2 sensor? Respir Physiol Neurobiol (2010) 0.98
The oxygen sensing signal cascade under the influence of reactive oxygen species. Philos Trans R Soc Lond B Biol Sci (2005) 0.93
Lung oxidative damage by hypoxia. Oxid Med Cell Longev (2012) 0.86
Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators. Br J Pharmacol (2002) 0.85
Mitochondrial complex III: an essential component of universal oxygen sensing machinery? Respir Physiol Neurobiol (2010) 0.83
Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. Respir Res (2005) 0.82
Role of ROS signaling in differential hypoxic Ca2+ and contractile responses in pulmonary and systemic vascular smooth muscle cells. Respir Physiol Neurobiol (2010) 0.81
Thiazolidinediones prevent PDGF-BB-induced CREB depletion in pulmonary artery smooth muscle cells by preventing upregulation of casein kinase 2 alpha' catalytic subunit. J Cardiovasc Pharmacol (2010) 0.80
Mitochondria control acute and chronic responses to hypoxia. Exp Cell Res (2017) 0.75
An Update on Pulmonary Arterial Hypertension. J Nurse Pract (2015) 0.75
NADPH oxidases-do they play a role in TRPC regulation under hypoxia? Pflugers Arch (2015) 0.75
Making sense of oxygen sensing. J Physiol (2001) 0.75
NOX Modifiers-Just a Step Away from Application in the Therapy of Airway Inflammation? Antioxid Redox Signal (2014) 0.75
Oxygen Toxicity and Special Operations Forces Diving: Hidden and Dangerous. Front Psychol (2017) 0.75
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child (1976) 3.71
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood (1990) 2.54
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer (2007) 2.00
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol (2000) 1.73
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Qualitative scale for estimating sulphur dioxide air pollution in Engand and Wales using epiphytic lichens. Nature (1970) 1.59
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J (2010) 1.57
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Recovery from withdrawal of inhaled nitric oxide and kinetics of nitric oxide-induced inhibition of nitric oxide synthase activity in vitro. Intensive Care Med (2000) 1.40
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
Myoclonus secondary to the concurrent use of trazodone and fluoxetine. Vet Hum Toxicol (2001) 1.39
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis (1989) 1.27
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Evaluation of the Titertek Multiskan for determining minimal inhibitory concentration endpoints. Antimicrob Agents Chemother (1982) 1.21
Antimicrobial peptides in the gastrointestinal tract. Gut (1997) 1.21
Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am J Respir Crit Care Med (2001) 1.21
Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol (2006) 1.19
The listerial exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C synergize to elicit endothelial cell phosphoinositide metabolism. J Immunol (1996) 1.17
Human endothelial cell activation and mediator release in response to Listeria monocytogenes virulence factors. Infect Immun (2001) 1.16
Microsurgical unilateral approaches for spinal tumour surgery: eight years' experience in 256 primary operated patients. Acta Neurochir (Wien) (1989) 1.16
Effects of Escherichia coli hemolysin on endothelial cell function. Infect Immun (1990) 1.16
Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J Clin Invest (1991) 1.13
Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol (1986) 1.13
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med (2001) 1.13